Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.
Pontiroli
A E
AE
Istituto Scientifico San Raffaele, Cattedra di Clinica Medica, Università di Milano, Italy.
Calderara
A
A
Pozza
G
G
D000281:Administration, Intranasal; D002116:Calcitonin / Q000008:administration & dosage; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage; D005934:Glucagon / Q000008:administration & dosage; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D010455:Peptides / Q000008:administration & dosage* / Q000493:pharmacokinetics
D007328:Insulin; D010455:Peptides; D002116:Calcitonin; D005934:Glucagon; D003346:Corticotropin-Releasing Hormone; D013007:Growth Hormone-Releasing Hormone